Literature DB >> 1064436

Ultrastructure of chronic megakaryocytic-granulocytic myelosis.

J Thiele, A Georgii, K F Vykoupil.   

Abstract

To study chronic megakaryocytic-granulocytic myelosis, bone marrow biopsies from 5 patients were obtained. Ultrastructural quantitative and qualitative assessments demonstrate proliferation of both the megakaryocytic and granulocytic cell lines. Factors indicative of malignant growth in megakaryocytes included atypical maturation, nuclear-cytoplasmic asynchrony, nuclear inclusions and production of micromegakaryocytes. Abnormal thrombocyte delineation provoked giant platelet production. The neutrophil series also presented atypia as generally observed in chronic myelogenous leukemia. Even in cases without evidence of myelofibrosis under the light microscope, megakaryoblasts were associated with fibrillar structures. These cells may be responsible for the initial step in fibrillogenesis by providing a medium conductive to the collagen formation found in later stages of this disease.

Entities:  

Mesh:

Year:  1976        PMID: 1064436     DOI: 10.1007/bf01013883

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  3 in total

1.  Fine structure and peroxidase activity of circulating micromegakaryoblasts and platelets in a case of acute myelofibrosis.

Authors:  J B Gorius; M T Daniel; G Flandrin; G K Denoel
Journal:  Br J Haematol       Date:  1973-09       Impact factor: 6.998

2.  Dysplastic platelets and circulating megakaryocytes in chronic myeloproliferative diseases. I. The platelets: ultrastructure and peroxidase reaction.

Authors:  J E Maldonado; T Pintado; R V Pierre
Journal:  Blood       Date:  1974-06       Impact factor: 22.113

3.  Dysplastic platelets and circulating megakaryocytes in chronic myeloproliferative diseases. II. Ultrastructure of circulating megakaryocytes.

Authors:  J E Maldonado
Journal:  Blood       Date:  1974-06       Impact factor: 22.113

  3 in total
  3 in total

Review 1.  Overview of Myeloproliferative Neoplasms: History, Pathogenesis, Diagnostic Criteria, and Complications.

Authors:  Douglas Tremblay; Abdulraheem Yacoub; Ronald Hoffman
Journal:  Hematol Oncol Clin North Am       Date:  2021-01-26       Impact factor: 3.722

2.  Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria.

Authors:  Elisa Rumi; Emanuela Boveri; Marta Bellini; Daniela Pietra; Virginia V Ferretti; Emanuela Sant'Antonio; Chiara Cavalloni; Ilaria C Casetti; Elisa Roncoroni; Michele Ciboddo; Pietro Benvenuti; Benedetta Landini; Elena Fugazza; Daniela Troletti; Cesare Astori; Mario Cazzola
Journal:  Oncotarget       Date:  2017-10-06

Review 3.  Prefibrotic myelofibrosis: treatment algorithm 2018.

Authors:  Guido Finazzi; Alessandro M Vannucchi; Tiziano Barbui
Journal:  Blood Cancer J       Date:  2018-11-07       Impact factor: 11.037

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.